Oscar Health Expects FY23 Adjusted EBITDA Loss Of ($60)M-($50)M, Above High-end Of The Prior Range Of ($175)M-($75)M, Forecasts Direct And Assumed Policy Premiums At High-end Of $6.4B-$6.6B Range
Portfolio Pulse from Benzinga Newsdesk
Oscar Health has revised its FY23 adjusted EBITDA loss forecast to between $50M and $60M, which is above the high-end of the previous range of $75M to $175M. The company also expects its direct and assumed policy premiums to be at the high-end of the $6.4B to $6.6B range.
November 07, 2023 | 11:09 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Oscar Health's revised FY23 adjusted EBITDA loss forecast is better than previously expected, which could be positive for the stock. However, the company is still expecting a significant loss, which could limit any potential gains.
Oscar Health's revised forecast indicates a smaller loss than previously expected, which could be seen as a positive sign by investors. However, the company is still expecting a significant loss, which could limit any potential gains in the stock price. The news is highly relevant to Oscar Health as it directly pertains to the company's financial performance.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100